Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the ...

For details, see the “Before receiving Ultomiris” section. With myasthenia gravis, dysfunctional muscle ... begins with a loading dose. Two weeks after the loading dose, you’ll continue ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with myasthenia gravis. Poster presented at: AMCP 2025; March 31-April 3 ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and ...